$0.86-0.04 (-4.50%)
News25/Ratings2
Price$0.86-0.06 (-6.46%)
02:15 PM07:45 PM
News · 26 weeks61+17%
2025-10-262026-04-19
Mix3590d
- Other12(34%)
- Insider10(29%)
- SEC Filings8(23%)
- Leadership2(6%)
- Earnings2(6%)
- Offering1(3%)
Latest news
25 items- PRRenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual MeetingMOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, entitled "The TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gem
- SECSEC Form S-3 filed by RenovoRx Inc.S-3 - RenovoRx, Inc. (0001574094) (Filer)
- PRClinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific MeetingData Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer Metabolic Imaging, Used to Evaluate Therapeutic Outcome Following Treatment with TAMP, Shows a Notable Reduction in Tumor Activity Suggesting a Potential Treatment Response MOUNTAIN VIEW, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract submitted by experts from Moffitt C
- SECSEC Form D filed by RenovoRx Inc.D - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa VasorumPatent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with 19 Issued or Allowed Patents and 14 Pending Patents Supporting the Commercialization of the RenovoCath Device MOUNTAIN VIEW, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that the Japan Patent Office (JPO) has issued a Notice of Allowance for the Company's first Japane
- INSIDERSEC Form 4 filed by Bagai Shaun4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Voll Mark4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Gentry Leesa4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Agah Ramtin4 - RenovoRx, Inc. (0001574094) (Issuer)
- PRRenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has been named on Fast Company's prestigious list of the World's Most Innovative Companies of 2026 as number 10 in the medical device category. This annual recognition highlights organizations that are shaping industry and culture through their innovations. "We're honored to be named one of the 2026 World's Most Innovative Medical Device Companies by Fast Company," said Shaun Bagai, Chief Executive
- SECSEC Form S-8 filed by RenovoRx Inc.S-8 - RenovoRx, Inc. (0001574094) (Filer)
- SECRenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - RenovoRx, Inc. (0001574094) (Filer)
- SECSEC Form 10-K filed by RenovoRx Inc.10-K - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx Reports Full Year 2025 Financial Results and Provides Business UpdateRenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f
- INSIDERSEC Form 4 filed by Voll Mark4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Voll Mark3/A - RenovoRx, Inc. (0001574094) (Issuer)
- SECSEC Form 8-K filed by RenovoRx Inc.8-K - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of EnrollmentTIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath® as a Stand-Alone Device for Drug-Delivery in Oncology Management MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the Company has achieved a key milestone in its ongoing Phase III TIGeR‑PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion
- INSIDERSEC Form 4 filed by Marton Laurence4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Bagai Shaun4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 4 filed by Voll Mark4 - RenovoRx, Inc. (0001574094) (Issuer)
- INSIDERSEC Form 3 filed by new insider Voll Mark3 - RenovoRx, Inc. (0001574094) (Issuer)
- PRRenovoRx Announces Closing of Oversubscribed $10 Million at Market Private PlacementMOUNTAIN VIEW, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the closing of its previously announced, oversubscribed private placement of common stock and revenue milestone warrants. The private placement resulted in gross proceeds of approximately $10 million to RenovoRx, before deducting offering expenses. The financing was led by new and existing institutional investors, including Transcend Partners, LLC, AIGH Capital Management LLC, Bleichroeder, LP and Pathfinde
- SECRenovoRx Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - RenovoRx, Inc. (0001574094) (Filer)
- PRRenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ETMOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx's management team is expected to discuss the continued progress in RenovoCath adoption among U.S. cancer centers,